Pneumonia caused by Pseudomonas aeruginosa occurs frequently in critically ill patients and is associated with a mortality rate of 70 per cent. An aerosol of polymyxin B was administered (2.5 mg per kilogram per day) to the upper airways of 292 patients in a respiratory-surgical intensive-care unit during a seven-month period, in an attempt to prevent Ps. aeruginosa pneumonia. Although only one of the patients studied acquired pneumonia due to Ps. aeruginosa, 10 others acquired pneumonia caused by a polymysinx-resistant organism. Seven pneumonias were caused by organisms not frequently pathogenic to man (flavobacteria, serratia and Streptococcus faecalis). The mortality rate for acquired pneumonia in this study, 64 per cent, is greater than that in previous studies in which either no polymyxin or cyclic polymyxin therapy was used. Continuous use of polymyxin B aerosol appears to be a dangerous form of therapy.
This article has been cited by other articles:
Peleg, A. Y., Seifert, H., Paterson, D. L.
(2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev.
21: 538-582
[Abstract][Full Text]
Ioannidou, E., Siempos, I. I., Falagas, M. E.
(2007). Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother
60: 1216-1226
[Abstract][Full Text]
Arnold, T. M., Forrest, G. N., Messmer, K. J.
(2007). Polymyxin antibiotics for gram-negative infections. Am J Health Syst Pharm
64: 819-826
[Abstract][Full Text]
Morar, P, Singh, V, Makura, Z, Jones, A S, Baines, P B, Selby, A, Sarginson, R, Hughes, J, van Saene, R
(2002). Oropharyngeal carriage and lower airway colonisation/infection in 45 tracheotomised children. Thorax
57: 1015-1020
[Abstract][Full Text]
Aarts, M.-A., Marshall, J. C.
(2002). In Defense of Evidence: The Continuing Saga of Selective Decontamination of the Digestive Tract. Am. J. Respir. Crit. Care Med.
166: 1014-1015
[Full Text]
Chastre, J., Fagon, J.-Y.
(2002). Ventilator-associated Pneumonia. Am. J. Respir. Crit. Care Med.
165: 867-903
[Abstract][Full Text]
Prober, C. G., Walson, P. D., Jones, J., the Committee on Infectious Diseases and Committee,
(2000). Technical Report: Precautions Regarding the Use of Aerosolized Antibiotics. Pediatrics
106: 89e-89
[Abstract][Full Text]
Campbell, P. W. III, Saiman, L.
(1999). Use of Aerosolized Antibiotics in Patients With Cystic Fibrosis. Chest
116: 775-788
[Full Text]
Denton, M., Todd, N. J., Kerr, K. G., Hawkey, P. M., Littlewood, J. M.
(1998). Molecular Epidemiology of Stenotrophomonas maltophilia Isolated from Clinical Specimens from Patients with Cystic Fibrosis and Associated Environmental Samples. J. Clin. Microbiol.
36: 1953-1958
[Abstract][Full Text]
Denton, M., Kerr, K. G.
(1998). Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia. Clin. Microbiol. Rev.
11: 57-80
[Abstract][Full Text]
Craven, D. E.
(1992). Use of Selective Decontamination of the Digestive Tract: Is the Light at the End of the Tunnel Red or Green?. ANN INTERN MED
117: 609-611
[Abstract]
Pugin, J., Auckenthaler, R., Lew, D. P., Suter, P. M.
(1991). Oropharyngeal Decontamination Decreases Incidence of Ventilator-Associated Pneumonia: A Randomized, Placebo-Controlled, Double-blind Clinical Trial. JAMA
265: 2704-2710
[Abstract]
Brun-Buisson, C., Legrand, P., Rauss, A., Richard, C., Montravers, F., Besbes, M., Meakins, J. L., Soussy, C. J., Lemaire, F.
(1989). Intestinal Decontamination for Control of Nosocomial Multiresistant Gram-Negative Bacilli: Study of an Outbreak in an Intensive Care Unit. ANN INTERN MED
110: 873-881
[Abstract]
SHAKESPEARE, W., MAKI, D. G.
(1989). Risk Factors for Nosocomial Infection in Intensive Care: 'Devices vs Nature' and Goals for the Next Decade. Arch Intern Med
149: 30-35
[Abstract]
Le, C. T.
(1977). Antimicrobial Therapy. JAMA
238: 852-853
[Abstract]
Veterans Administration Ad Hoc Interdisciplinary A,
(1977). 7. Parenteral Polymyxin B and Colistimethate. JAMA
237: 1481-1482
Previous
